Loading lessons…
Peptide learning paths
Learn peptides step by step
Curated lessons across 8 learning paths — from first concepts to trial summaries and practical protocols. Pick your level, follow the curriculum, and build real understanding.
Where are you starting?
272lessons
8paths
0day streak
0%explored
Start your first lesson
Choose a learning path below or search the library. Progress saves in your browser.
Prefer timeline chaos? Peptide X Quiz · Literacy certify
Learning paths
Pick a track — progress rings update as you complete lessons.
10 lessons
10mProtocolsIntermediate
BPC-157 Reconstitution and Dosing: What the Literature Actually Reports
Most BPC-157 dose threads treat forum tables as fact. This guide separates published animal and limited human data from observational ranges people log, without turning either into a protocol.
9mPeptidesIntermediate
August 14, 2026 Peptide Research Signals: What to Watch Next
The newest peptide research batch is less about hype and more about the questions each compound answers. Retatrutide, tesamorelin, BPC-157, GHK-Cu, and MOTS-C all point at different tracking priorities.
12mInsightsIntermediate
PeptIQ H1 2026 Report: What Thousands of Real Peptide Logs Reveal
Retatrutide dominates H1 logging, the Wolverine stack is real, and quick-log onboarding predicts who actually tracks. Our first semi-annual data report from thousands of real peptide logs.
9mPeptidesIntermediate
Injectable Peptides in Sports Medicine: What the Evidence and Antidoping Rules Actually Say
Sports medicine keeps pulling peptides into the conversation because recovery pressure is real. The hard part is separating promising biology from weak evidence, gray-market hype, and antidoping risk.
7mResearchAdvanced
GLP-1s Before Bariatric Surgery: What the 2026 Evidence Says
GLP-1 peptides are changing the bariatric surgery conversation. The practical lesson is not self-managing around surgery. It is better tracking, clearer handoffs, and coordinated medical planning.
7mResearchAdvanced
Peptide Regulation and Sourcing Safety in 2026
The biggest peptide trend in 2026 may not be a molecule. It may be oversight, sourcing quality, and the ability to separate evidence from marketing.
7mResearchAdvanced
Efsubaglutide Alfa SUPER1 Trial: What the New GLP-1 Data Shows
Efsubaglutide alfa is a long-acting GLP-1 receptor agonist with new human trial data in drug-naive type 2 diabetes. Here is what the SUPER1 results actually show.
7mSafetyIntermediate
Peptides and Ehlers-Danlos Syndrome: What to Know Before You Experiment
EDS changes the safety conversation around peptides. GHK-Cu, BPC-157, and TB-500 are discussed for tissue support, but EDS plus cardiac history should stay clinician-led.
7mStart hereBeginner
Peptides for Women: What to Know Before You Start
Women have unique considerations with peptides, from hormones and cycle changes to muscle retention, recovery, skin health, and tracking.
8mStart hereBeginner
503a vs 503b vs Unapproved Peptide Status: What's the Difference?
Confused about peptide compounding categories? This guide breaks down 503a compounding pharmacies, 503b outsourcing facilities, and why “research use only” is not a consumer pathway PeptIQ endorses.
Also available at /blog for legacy links.